{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T15:28:25Z","timestamp":1787930905416,"version":"build-2784847793"},"reference-count":12,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.farma.2025.12.010","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T12:13:32Z","timestamp":1770207212000},"page":"308-311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quality of life and effectiveness of vutrisiran as treatment for hereditary transthyretin amyloidosis"],"prefix":"10.1016","volume":"50","author":[{"given":"Javier","family":"Coraz\u00f3n Villanueva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Andrea","family":"Garc\u00eda Sacrist\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.farma.2025.12.010_bb0005","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1474-4422(23)00334-4","article-title":"Hereditary transthyretin amyloid neuropathies: advances in pathophysiology, biomarkers, and treatment","volume":"22","author":"Adams","year":"2023","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1016\/j.farma.2025.12.010_bb0010","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1750-1172-8-31","article-title":"Guideline of transthyretin-related hereditary amyloidosis for clinicians","volume":"20","author":"Ando","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"10.1016\/j.farma.2025.12.010_bb0015","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.nrl.2016.07.009","article-title":"Polineuropat\u00eda amiloid\u00f3tica familiar por mutaci\u00f3n Val50Met (Val30Met) en el gen de la transtiretina","volume":"33","author":"Andr\u00e9s","year":"2018","journal-title":"Neurologia"},{"key":"10.1016\/j.farma.2025.12.010_bb0020","author":"Amvuttra\u00ae (Vutrisiran) [Ficha t\u00e9cnica] Acceso el 22 enero 2025"},{"issue":"1","key":"10.1016\/j.farma.2025.12.010_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"issue":"1","key":"10.1016\/j.farma.2025.12.010_bb0030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.farma.2025.12.010_bb0035","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/jns5.12059","article-title":"Norfolk QOL-DN: Validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy","volume":"19","author":"Vinik","year":"2014","journal-title":"J Peripher Nerv Syst"},{"issue":"4","key":"10.1016\/j.farma.2025.12.010_bb0040","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/annonc\/mdw685","article-title":"Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab)","volume":"28","author":"Rummel","year":"2017","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.farma.2025.12.010_bb0045","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1007\/s13311-021-01154-y","article-title":"Current and emerging therapies for hereditary transthyretin amyloidosis: strides towards a brighter future","volume":"18","author":"Obici","year":"2021","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.farma.2025.12.010_bb0050","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13023-020-1340-x","article-title":"Health-related quality of life in hereditary transthyretin amyloidosis polyneuropathy: a prospective, observational study","volume":"15","author":"In\u00eas","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"10.1016\/j.farma.2025.12.010_bb0055","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1007\/s13311-021-01154-y","article-title":"Current and emerging therapies for hereditary transthyretin amyloidosis: strides towards a brighter future","volume":"18","author":"Obici","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.farma.2025.12.010_bb0060","author":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Informe de Posicionamiento Terap\u00e9utico de Vutrisir\u00e1n (Amvuttra\u00ae) en el tratamiento de la amiloidosis hereditaria por transtiretina"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634326000048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634326000048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T15:08:20Z","timestamp":1787929700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634326000048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1130634326000048"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2025.12.010","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quality of life and effectiveness of vutrisiran as treatment for hereditary transthyretin amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2025.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}